ALX Oncology Holdings Inc. has announced positive results from an ongoing Phase 2 investigator-sponsored trial evaluating evorpacept (ALX148) in combination with standard-of-care rituximab and lenalidomide for patients with untreated indolent B-cell non-Hodgkin lymphoma (iNHL). The study reported a complete response rate of 92% with the combination therapy, comparing favorably to an approximate historical 50% complete response rate for rituximab and lenalidomide alone. The regimen was reported to be well-tolerated and demonstrated notable anti-tumor activity in the frontline treatment setting. These data are being presented at the American Society of Hematology $(ASH)$ Annual Meeting 2025 in Orlando, Florida, during a poster session on December 7, 2025. Further evaluation of minimal residual disease eradication rates is planned as the trial follow-up continues.